Journal article
IL-11 signaling as a therapeutic target for cancer
Tracy L Putoczki, Matthias Ernst
IMMUNOTHERAPY | FUTURE MEDICINE LTD | Published : 2015
DOI: 10.2217/IMT.15.17
Abstract
IL-11 is a member of the IL-6 family of cytokines. While it was discovered over 20 years ago, we have very little understanding of the role of IL-11 during normal homeostasis and disease. Recently, IL-11 has gained interest for its newly recognized role in the pathogenesis of diseases that are attributed to deregulated mucosal homeostasis, including gastrointestinal cancers. IL-11 can increase the tumorigenic capacity of cells, including survival of the cell or origin, proliferation of cancerous cells and survival of metastatic cells at distant organs. Here we outline our current understanding of IL-11 biology and recent advances in our understanding of its role in cancer. We advocate that i..
View full abstractGrants
Awarded by NHMRC
Awarded by Worldwide Cancer Research
Funding Acknowledgements
The work in the laboratory of M Ernst is supported by the Ludwig Institute for Cancer Research. The work in the laboratories of M Ernst and TL Putoczki is supported by the Victorian State Government Operational Infrastructure Support, and NHMRC grants 1008614 and 1080498 (to TL Putoczki) and 603122, 1064987, 1069024 and 1079257 (to M Ernst) and WCRF, formally AICR (to TL Putoczki). Both authors are inventors of patents describing the use of IL-11 antagonists for the treatment of cancer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.